[go: up one dir, main page]

AR052565A1 - Prevencion y tratamiento de trastornos tromboembolicos - Google Patents

Prevencion y tratamiento de trastornos tromboembolicos

Info

Publication number
AR052565A1
AR052565A1 ARP060100331A ARP060100331A AR052565A1 AR 052565 A1 AR052565 A1 AR 052565A1 AR P060100331 A ARP060100331 A AR P060100331A AR P060100331 A ARP060100331 A AR P060100331A AR 052565 A1 AR052565 A1 AR 052565A1
Authority
AR
Argentina
Prior art keywords
day
prevention
treatment
thromboembolic disorders
refers
Prior art date
Application number
ARP060100331A
Other languages
English (en)
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR052565(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of AR052565A1 publication Critical patent/AR052565A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se refiere al campo de la coagulacion sanguínea, más específicamente se refiere a un método de tratamiento de un trastorno tromboembolico mediante la administracion de un inhibidor directo del factor Xa una vez al día en forma de dosificacion oral a un paciente necesitado de ello, en el que el inhibidor del factor Xa tiene una semivida de concentracion plasmática indicativa de un intervalo de administracion dos veces al día (bid) o tres veces al día (tid), por ejemplo, de 10 horas o menos.
ARP060100331A 2005-01-31 2006-01-30 Prevencion y tratamiento de trastornos tromboembolicos AR052565A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05001893A EP1685841A1 (en) 2005-01-31 2005-01-31 Prevention and treatment of thromboembolic disorders

Publications (1)

Publication Number Publication Date
AR052565A1 true AR052565A1 (es) 2007-03-21

Family

ID=34933512

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060100331A AR052565A1 (es) 2005-01-31 2006-01-30 Prevencion y tratamiento de trastornos tromboembolicos
ARP170103610A AR110413A2 (es) 2005-01-31 2017-12-20 Compuesto 5-cloro-n-((5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-ilmetil)-2-tiofencarboxamida

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170103610A AR110413A2 (es) 2005-01-31 2017-12-20 Compuesto 5-cloro-n-((5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-ilmetil)-2-tiofencarboxamida

Country Status (27)

Country Link
US (1) US9539218B2 (es)
EP (2) EP1685841A1 (es)
JP (1) JP2008528527A (es)
KR (1) KR20070107009A (es)
CN (1) CN101111236A (es)
AR (2) AR052565A1 (es)
AU (1) AU2006208613B2 (es)
BR (1) BRPI0606760A2 (es)
CA (1) CA2596145A1 (es)
CY (1) CY1116494T1 (es)
DK (1) DK1845961T3 (es)
ES (1) ES2542335T3 (es)
HR (1) HRP20150764T1 (es)
HU (1) HUE025705T4 (es)
IL (1) IL184585A0 (es)
MA (1) MA29236B1 (es)
MX (1) MX2007009100A (es)
NO (1) NO344278B1 (es)
NZ (1) NZ556765A (es)
PL (1) PL1845961T3 (es)
PT (1) PT1845961E (es)
SG (1) SG159505A1 (es)
SI (1) SI1845961T1 (es)
TW (1) TWI377945B (es)
UA (1) UA91355C2 (es)
WO (1) WO2006079474A1 (es)
ZA (1) ZA200706238B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
EP1934208B1 (de) 2005-10-04 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Neue polymorphe form von 5-chlor-n-({ ( 5s )-2-0x0-3-[4-( 3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl} -methyl)-2-thiophencarboxamid
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
US7816355B1 (en) * 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
EP4148045A1 (en) 2010-01-27 2023-03-15 Arena Pharmaceuticals, Inc. Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof
EP2538360A1 (en) * 2011-06-16 2012-12-26 Koninklijke Philips Electronics N.V. Method of predicting a blood dilution risk value
JP2016529279A (ja) * 2013-08-29 2016-09-23 第一三共株式会社 がんの治療又は予防のための剤
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
AU2018222747A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
US20210244698A1 (en) * 2018-07-30 2021-08-12 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use with thrombectomy and embolectomy and other vascular disease procedures

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2811555A (en) 1955-05-02 1957-10-29 Eastman Kodak Co Reduction of 2-nitroso-5-diethylaminotoluene
US3279880A (en) 1965-07-12 1966-10-18 Eastman Kodak Co Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
LU80081A1 (fr) 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4500519A (en) 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
HU190072B (en) 1983-03-11 1986-08-28 Biogal Gyogyszergyar,Hu Process for production of medical preparatives with sinergetic influence
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
ES8506659A1 (es) 1983-06-07 1985-08-01 Du Pont Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno.
US4977173A (en) 1987-10-21 1990-12-11 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
EP0316594B1 (en) 1987-10-21 1993-09-29 The Du Pont Merck Pharmaceutical Company Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5254577A (en) 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
KR100257418B1 (ko) 1991-11-01 2000-05-15 로렌스 티. 마이젠헬더 치환된 아릴-및 헤테로아릴-페닐옥사졸리디논
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
US5349045A (en) 1993-01-26 1994-09-20 United States Surgical Corporation Polymer derived from cyclic amide and medical devices manufactured therefrom
ES2134870T3 (es) 1993-05-01 1999-10-16 Merck Patent Gmbh Antagonistas del receptor de adhesion.
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE4332384A1 (de) 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
CZ231497A3 (cs) 1995-02-03 1998-08-12 Pharmacia & Upjohn Company Antimikrobiální fenyloxazolidinony substituované heteroaromatickým kruhem
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
US5798375A (en) 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
DE19524765A1 (de) 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US5968962A (en) 1995-09-01 1999-10-19 Pharmacia & Upjohn Company Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings
EP1019385B1 (en) 1995-09-15 2004-01-14 PHARMACIA & UPJOHN COMPANY Aminoaryl oxazolidinone n-oxides
DE19601264A1 (de) 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
HRP970049A2 (en) 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
DE19604223A1 (de) 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
GB9614238D0 (en) 1996-07-06 1996-09-04 Zeneca Ltd Chemical compounds
ES2250283T3 (es) 1996-07-15 2006-04-16 Sankyo Company Limited Uso de cs-866 (olmesartan) en la preparacion de un medicamento para el tratamiento de la arteriosclerosis.
US5935724A (en) 1997-04-04 1999-08-10 Wilson Greatbatch Ltd. Electrochemical cell having multiplate electrodes with differing discharge rate regions
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
WO1998054161A1 (en) 1997-05-30 1998-12-03 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
NZ502253A (en) 1997-07-11 2001-06-29 Upjohn Co Thiadiazolyl and oxadiazolyl phenyl oxazolidinone derivatives which are antibacterial agents
DE19730847A1 (de) 1997-07-18 1999-01-28 Bayer Ag Tricyclisch substituierte Oxazolidinone
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
CN1154644C (zh) 1997-11-12 2004-06-23 法玛西雅厄普约翰美国公司 噁唑烷酮衍生物和药物组合物
US6083967A (en) 1997-12-05 2000-07-04 Pharmacia & Upjohn Company S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones
DE19755268A1 (de) 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidinderivate
WO1999037630A1 (en) 1998-01-23 1999-07-29 Versicor, Inc. Oxazolidinone combinatorial libraries, compositions and methods of preparation
AU745425B2 (en) 1998-01-27 2002-03-21 Aventis Pharmaceuticals Inc. Substituted oxoazaheterocyclyl factor Xa inhibitors
DE19805117A1 (de) 1998-02-09 1999-08-12 Bayer Ag Neue Oxazolidinone mit azolhaltigen Tricyclen
US20010029351A1 (en) 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
DE69902526T2 (de) 1998-05-18 2003-04-03 Pharmacia & Upjohn Co., Kalamazoo Verbesserung der antibakteriellen wirkung von oxazolidinon durch arginin derivate
DE19842753A1 (de) 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
PE20010851A1 (es) 1999-12-14 2001-08-17 Upjohn Co Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina
CZ20022142A3 (cs) 1999-12-21 2002-11-13 Pharmacia & Upjohn Company Oxazolidinony mající sulfoximinovou funkční skupinu
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
EP1245573A1 (en) 1999-12-28 2002-10-02 Ajinomoto Co., Inc. Aspartame derivative crystals
KR100415318B1 (ko) 2000-09-23 2004-01-16 탁승호 레이저를 이용한 수평 및 수직선 지시계
DE10105989A1 (de) 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10110438A1 (de) 2001-03-05 2002-09-19 Bayer Ag Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10110754A1 (de) 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115922A1 (de) 2001-03-30 2002-10-10 Bayer Ag Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115945A1 (de) 2001-03-30 2002-10-02 Bayer Ag Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10134481A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10152460A1 (de) 2001-10-24 2003-05-08 Bayer Ag Stents
DE10238113A1 (de) 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004002044A1 (de) 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
EP1934208B1 (de) 2005-10-04 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Neue polymorphe form von 5-chlor-n-({ ( 5s )-2-0x0-3-[4-( 3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl} -methyl)-2-thiophencarboxamid
DE102005047558A1 (de) 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102005048824A1 (de) 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien

Also Published As

Publication number Publication date
AU2006208613A1 (en) 2006-08-03
PL1845961T3 (pl) 2015-09-30
JP2008528527A (ja) 2008-07-31
CN101111236A (zh) 2008-01-23
EP1685841A1 (en) 2006-08-02
HRP20150764T1 (hr) 2015-08-28
ZA200706238B (en) 2008-11-26
AR110413A2 (es) 2019-03-27
NZ556765A (en) 2010-11-26
EP1845961A1 (en) 2007-10-24
SI1845961T1 (sl) 2015-08-31
MA29236B1 (fr) 2008-02-01
US9539218B2 (en) 2017-01-10
CY1116494T1 (el) 2017-03-15
ES2542335T3 (es) 2015-08-04
MX2007009100A (es) 2007-09-13
NO344278B1 (no) 2019-10-28
SG159505A1 (en) 2010-03-30
UA91355C2 (ru) 2010-07-26
CA2596145A1 (en) 2006-08-03
HUE025705T4 (hu) 2023-02-28
NO20074356L (no) 2007-08-27
EP1845961B1 (en) 2015-04-22
TW200640441A (en) 2006-12-01
IL184585A0 (en) 2008-12-29
PT1845961E (pt) 2015-08-31
DK1845961T3 (en) 2015-07-20
AU2006208613B2 (en) 2011-06-16
KR20070107009A (ko) 2007-11-06
US20090004265A1 (en) 2009-01-01
TWI377945B (en) 2012-12-01
BRPI0606760A2 (pt) 2009-07-14
WO2006079474A1 (en) 2006-08-03
HUE025705T2 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
AR052565A1 (es) Prevencion y tratamiento de trastornos tromboembolicos
CY1120022T1 (el) Θεραπεια παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας
CY1115350T1 (el) Χρησεις αναστολεων της dpp iv
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
CY1118311T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις comt που χορηγουνται με ειδικη αγωγη δοσολογιας
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
EA201490254A1 (ru) Комбинированное лечение гепатита с
ATE511392T1 (de) Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
NO20082120L (no) Behandling og forebyggelse av mikroangiopati
NI200900106A (es) Inhibidores de la actividad de la akt.
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
CO6220969A2 (es) Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
UY26422A1 (es) Método para administrar un inhibidor de fosfodiesterasa 4
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
WO2007123511A3 (en) Dosing regimens for the treatment of cancer
ATE421882T1 (de) Schnellösliches azithromycin in einzeldosisform
DE602006021348D1 (de) Feste form von amg 706 und pharmazeutische zusammensetzungen davon
NO20080495L (no) PEG-IFN-alfa og ribavirin for HBV-behandling

Legal Events

Date Code Title Description
FC Refusal